Pacira BioSciences
PCRX
About: Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Employees: 790
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
220% more call options, than puts
Call options by funds: $7.02M | Put options by funds: $2.2M
8% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 77
0.09% less ownership
Funds ownership: 109.24% [Q1] → 109.15% (-0.09%) [Q2]
4% less capital invested
Capital invested by funds: $1.26B [Q1] → $1.21B (-$48.8M) [Q2]
6% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 32
2% less funds holding
Funds holding: 234 [Q1] → 230 (-4) [Q2]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]
Financial journalist opinion
